/C O R R E C T I O N -- Agendia B.V./

In the news release, "Agendia's Breast Cancer Recurrence Test MammaPrint
Included in International St. Gallen Expert Consensus Recommendations" issued
on 23 Jun 200912:00 GMT, by Agendia B.V. over PR Newswire, please be advised
that the subheadline was missing from the release as incorrectly transmitted
by PR Newswire. Complete, corrected release follows:
, /PRNewswire/ --
Agendia's Breast Cancer Recurrence Test MammaPrint Included in
International St. Gallen Expert Consensus Recommendations - International
Expert Panel Recommends Use of Multigene Profiling Assays and Finds
Intermediate Scores Lack Clinical Utility
HUNTINGTON BEACH, California and AMSTERDAM, June 23 2009 - Agendia, a
world leader in molecular cancer diagnostics, today announced the inclusion
of its breast cancer recurrence test MammaPrint in St. Gallen's 2009
International Expert Consensus on the primary therapy of early breast cancer.
The recommendations have been published online in the Annals of Oncology and
will appear in the August print edition.
The St. Gallen expert panel consists of key opinion leaders from across
Europe (53%), the United States (33%), and rest of the world (14%). In the
recently published article highlighting the 2009 recommendations, the
panellists emphasize that "in an important change from the previous St.
Gallen conference...the Panel supported the use of a validated multigene-
profiling assay, if readily available, as an adjunct to high-quality
phenotyping of breast cancer in cases in which the indication for adjuvant
chemotherapy remained uncertain."
In addition, the panel cautioned that so-called intermediate scores are
not useful in clinical decision making. Currently, MammaPrint is the only
breast cancer recurrence assay available that accurately yields a binary
result, without an intermediate group, addressing the panel's
recommendations. The FDA-cleared assay is always clinically useful and
indicates whether a patient is at low or high risk for metastasis and the
resulting clarity is vital in helping physicians personalize treatment
options.
"St. Gallen's guideline inclusion is a key step in further establishing
MammaPrint as a standard of care. It also supports our commitment to
upholding rigorous standards of quality and efficacy," said Dr. Bernhard
Sixt, Agendia's President and Chief Executive Officer. "With MammaPrint we
aim to provide breast cancer patients and their physicians with definitive
answers to crucial treatment questions."
In addition to MammaPrint, the company also offers TargetPrint to further
improve breast cancer treatment options. TargetPrint quantitatively
determines the gene expression levels of HER2neu, estrogen and progesterone
receptors. Ongoing research and development efforts continue to augment
Agendia's ability to accurately predict breast cancer recurrence, and help
physicians tailor individual treatment plans to their patients.
For online access to the Annals of Oncology:
http://annonc.oxfordjournals.org/cgi/content/full/mdp322v1

About Agendia
Agendia is at the forefront of the personalized medicine revolution,
striving to bring more effective, individualized treatment within reach of
patients. Building on a cutting edge genomics platform for tumor gene
expression profiling, the company's tests aim to help physicians more
accurately tailor cancer therapy. The company markets four products, with
several new genomic tests in development. Agendia collaborates with
pharmaceutical companies in the development of highly effective personalized
drugs in the area of oncology and was awarded the 2008 North American
Oncology Clinical Diagnostics Healthcare Innovation Award by Frost &
Sullivan. Agendia is based in Huntington Beach, California, and in Amsterdam,
The Netherlands. For more information please visit http://www.agendia.com.
SOURCE Agendia B.V.

Media contacts: Hans Herklots, Head of Corporate Communications, Agendia,
+31-20-462-1557 Office, +31-620-083-509 Mobile, hans.herklots@agendia.com.
Valerie Delva, Account Executive, Ricochet Public Relations, +1-212-679-3300
x131 Office, vdelva@ricochetpr.com